Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaHyperthermia as an adjunctive treatment for soft-tissue sarcoma
/in Hyperthermia, International Publications, Soft Tissue SarcomaThe extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer
/in International Publications, Newcastle Disease VirusVaccine therapy in patients with renal cell carcinoma
/in Hypernephroma, International Publications, IOZK VeröffentlichungenNewcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice
/in International Publications, Newcastle Disease VirusTh-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens
/in Dendritic Cells, International PublicationsPhysiological role of plasmacytoid dendritic cells and their potential use in cancer immunity
/in Dendritic Cells, International PublicationsIn vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection
/in HIV/AIDS, International PublicationsImmunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination
/in Dendritic Cells, International Publications, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer